John Manta, MD
Orthopaedic Surgery · Exton, PANPI 1518964832
Payments from drug & device makers
Across 58 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$274
- Zimmer Biomet$171
- Stryker$120
- Dynasplint Systems Inc.$116
- Johnson & Johnson$99
- Amniox Medical, Inc.$97
- plus $592 from 17 others
What the payments were for
- Food & beverage$1,45399%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 16 | $274 |
| Zimmer Biomet | 3 | $171 |
| Stryker | 2 | $120 |
| Dynasplint Systems Inc. | 3 | $116 |
| Johnson & Johnson | 6 | $99 |
| Amniox Medical, Inc. | 1 | $97 |
| Eclipse Technology Solutions Inc. | 2 | $83 |
| Bioventus LLC | 2 | $75 |
| Smith+Nephew | 3 | $57 |
| Vertex | 3 | $52 |
| Endo Pharmaceuticals Inc. | 3 | $48 |
| Ferring Pharmaceuticals Inc. | 2 | $39 |
| Heraeus Medical, LLC. | 1 | $36 |
| Medtronic | 1 | $33 |
| Zyla Life Sciences, Inc. | 2 | $31 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Davol Inc. | 1 | $20 |
| Solventum Corporation | 1 | $18 |
| ERMI LLC | 1 | $14 |
| Trice Medical, Inc. | 1 | $13 |
| Arteriocyte Medical Systems, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$1,470 in reported general payments places this provider in the 30th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 13 | $2,118 |
| Celecoxib | 65 | $1,786 |
| Cefadroxil | 54 | $1,685 |
| Oxycodone Hcl | 125 | $532 |
| Mupirocin | 46 | $306 |
| Meloxicam | 92 | $227 |
| Tramadol Hcl | 77 | $184 |
| Methylprednisolone | 16 | $125 |
| Cephalexin | 20 | $71 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Exton
- Kenan AksuExton$497K
- William HozackBensalem$10.6M
- Jess LonnerBryn Mawr$8.1M
- Gerald WilliamsBryn Mawr$6.8M
- Mark LazarusBensalem$6.4M
- John FenlinPhiladelphia$5.9M
- Peter SharkeyKing Of Prussia$5.7M
- Selene ParekhBensalem$4.9M
- Alexander VaccaroPhiladelphia$4.5M
- Joseph AbboudPhiladelphia$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.